Study Population: HIV-infected individuals between 18 and 50 years old who started similar antiretroviral therapy (ART) during chronic infection and remained virally suppressed for at least 48 weeks before enrollment. Participants will have CD4 >350 cells/μl at enrollment and a CD4 nadir >200 cells/μl.